<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85614">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01829750</url>
  </required_header>
  <id_info>
    <org_study_id>0329-18</org_study_id>
    <secondary_id>MHLW25040101</secondary_id>
    <nct_id>NCT01829750</nct_id>
  </id_info>
  <brief_title>Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease (PERSEUS)</brief_title>
  <official_title>Phase 2 Study of Intracoronary Infusion of Cardiac Progenitor Cells in Patients With Univentricular Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Okayama University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Research Informatics Center, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Okayama University</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of intracoronary infusion of
      cardiac progenitor cells in patients with univentricular heart disease. Patients with
      preoperative high-risk group or whose cardiac function did not recover postoperatively
      eventually have no choice other than heart transplantation.

      Following the safety verification of the Phase I study (TICAP trial) that has been
      implemented and completed, the efficacy will be verified in this Phase II clinical study.
      The rationale of this study is based on the animal studies that transplanted cardiac
      progenitor cells may regenerate damaged myocardium by giving rise to cardiac muscle and
      vascular cell types. Preclinical and phase I studies indicate the possibilities of cardiac
      function improvements and reduced myocardial fibrosis by progenitor cell infusion.

      The efficacy of cell transplantation is assessed as the primary endpoint of the Phase II
      clinical study. The improvements of cardiac ejection fraction assessed by echocardiography,
      ventriculography, and cardiac MRI, which are conducted before and after treatment, are
      assessed as the evaluation items. The absolute values of the improvement of cardiac ejection
      fraction obtained by the above three imaging modalities before and after treatment are
      compared between two groups of the transplantation group and non-transplantation group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>3 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary outcome measure is to evaluate the cardiac function improvement by echocardiography, ventriculography, and cardiac MRI, which are conducted before and 3 months after surgical treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The secondary outcome measure is to determine the cardiac function improvements by three different imaging modalities at 12 months after treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical symptoms</measure>
    <time_frame>3 and 12 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical symptoms and BNP levels will be assessed at 3- and 12-months after treatment and compared with control group.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hypoplastic Left Heart Syndrome</condition>
  <condition>Single Right Ventricle</condition>
  <condition>Single Left Ventricle</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>(Stage 1) No active intervention after standard surgical treatment
(Stage 2) Rescuing transplantation by cardiac progenitor cell infusion is applicable in patients, along with their written consent, 4 months after palliations who were assigned as control group in stage 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac progenitor cell infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Stage 1) single dose, intracoronary infusion of 0.3 million cells/kg cardiac progenitor cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Cardiac progenitor cell infusion</intervention_name>
    <description>(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group
(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Cardiac progenitor cell infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: Age is 0 year or more and 20 years or less at the time of enrollment.

          2. The patients have functional single ventricular physiology with the indication to
             have stage-2 or -3 palliative surgeries.

          3. The ventricular ejection fraction &lt;60%.

        Exclusion Criteria:

          1. Cardiogenic shock

          2. A patient with unstoppable extracorporeal circulation

          3. A patient with lethal, uncontrollable arrhythmia

          4. A patient with a complication of coronary artery disease

          5. A patient with a complication of brain dysfunction due to circulatory failure

          6. A patient with malignant neoplasm

          7. A patient with a complication of serious neurologic disorder

          8. A patient with high-grade pulmonary embolism or pulmonary hypertension

          9. A patient with high-grade renal failure

         10. A patient with multiple organ failure

         11. Active infection (including endocarditis)

         12. Sepsis

         13. Active hemorrhagic disease (e. g. gastrointestinal bleeding, injury)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidemasa Oh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Okayama University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hidemasa Oh, M.D., Ph.D.</last_name>
    <phone>+81-086-235-6506</phone>
    <email>hidemasa@md.okayama-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shunji Sano, M.D., Ph.D</last_name>
    <phone>+81-086-235-7359</phone>
    <email>s_sano@cc.okayama-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Okayama University</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidemasa Oh, M.D., Ph.D.</last_name>
      <phone>+81-086-235-6506</phone>
      <email>hidemasa@md.okayama-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Shunji Sano, M.D., Ph.D.</last_name>
      <phone>+81-086-235-7359</phone>
      <email>s_sano@cc.okayama-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Hidemasa Oh, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://shin-iryo.jp/section/index.html</url>
    <description>Center for Innovative Clinical Medicine</description>
  </link>
  <link>
    <url>http://okayama-u-cvs.jp/siniryo_english.html</url>
    <description>Okayama University Hospital</description>
  </link>
  <reference>
    <citation>Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML, Schneider MD. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12313-8. Epub 2003 Oct 6.</citation>
    <PMID>14530411</PMID>
  </reference>
  <reference>
    <citation>Tateishi K, Ashihara E, Honsho S, Takehara N, Nomura T, Takahashi T, Ueyama T, Yamagishi M, Yaku H, Matsubara H, Oh H. Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun. 2007 Jan 19;352(3):635-41. Epub 2006 Nov 27.</citation>
    <PMID>17150190</PMID>
  </reference>
  <reference>
    <citation>Tateishi K, Ashihara E, Takehara N, Nomura T, Honsho S, Nakagami T, Morikawa S, Takahashi T, Ueyama T, Matsubara H, Oh H. Clonally amplified cardiac stem cells are regulated by Sca-1 signaling for efficient cardiovascular regeneration. J Cell Sci. 2007 May 15;120(Pt 10):1791-800.</citation>
    <PMID>17502484</PMID>
  </reference>
  <reference>
    <citation>Tateishi K, Takehara N, Matsubara H, Oh H. Stemming heart failure with cardiac- or reprogrammed-stem cells. J Cell Mol Med. 2008 Dec;12(6A):2217-32. Epub 2008 Aug 27. Review.</citation>
    <PMID>18754813</PMID>
  </reference>
  <reference>
    <citation>Takehara N, Tsutsumi Y, Tateishi K, Ogata T, Tanaka H, Ueyama T, Takahashi T, Takamatsu T, Fukushima M, Komeda M, Yamagishi M, Yaku H, Tabata Y, Matsubara H, Oh H. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol. 2008 Dec 2;52(23):1858-65.</citation>
    <PMID>19038683</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>April 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Okayama University</investigator_affiliation>
    <investigator_full_name>Hidemasa Oh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Univentricular heart</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
